HOME >> BIOLOGY >> NEWS
Millennium and Bayer industrializing drug discovery process through ongoing successful research alliance

o years has been extraordinary, particularly given the usual three-year timeframe for the processing of targets, chemistry and pharmacology necessary to yield a developmental drug candidate, said Professor Wolfgang Hartwig, executive vice president of pharmaceuticals research at Bayer. As we celebrate our second anniversary with Millennium, we anticipate that in addition to our screening pipeline of more than 70 targets, we will have several preclinical compounds and potentially one chemical compound nearing IND status by year-end.

In May 2000, Millennium and Bayer expanded the initial objectives of the alliance, based on the success of their efforts. The two companies collectively accelerated their second year goal of identifying new validated drug targets from 50 to 100 by the end of 2000. To date, more than 70 validated drug targets have been identified since the alliance began in September 1998.
Bayer and Millennium have created the worlds leading platform for biologically annotating targets and moving them into drug discovery, said Mark Levin, chief executive officer of Millennium. Our joint efforts exemplify the power of Millennium's genomics-based approach to drug discovery and development, Bayers cutting-edge screening and chemistry capabilities and expertise, and the extraordinary success which can be created through over-the-top alliances.

Alliance Background The primary goal of the alliance is for Millennium to supply 225 important new drug targets identified as relevant for cardiovascular disease, cancer, pain, hematology and viral infections. From those identified by the alliance, Bayer will select drug targets for its exclusive use and the remainder will be available to Millennium to use in its proprietary drug development efforts.

In return for a total investment of up to $465 million, including an equity investment in Millennium over a five-year period, Bayer receives access to key technologies in modern genome
'"/>

Contact: Maureen Suda, Millennium Pharmaceuticals Inc.
617-551-2959
Porter Novelli
23-Oct-2000


Page: 1 2 3

Related biology news :

1. Millenniums LDP(PS)-341 inhibits growth and induces death of cancer cells, appears to overcome chemotherapy resistance
2. Science and Technology at the Millennium: Retrospect or Prospect Focus of AAAS Science and Technology Colloquium, April 11-13 in Washington, DC
3. Millennium and Wyeth-Ayerst announce the discovery of key potassium ion channel modulating proteins
4. Millennium and the Whitehead Institute identify novel protein important in fat absorption
5. Millennium Clones Diet-Induced Obesity Gene
6. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
7. New OHSU lab will speed drug discovery process
8. New discovery may help transplants survive
9. Genetic discovery could dramatically reduce need for liver transplants in children
10. Plant gene discovery could enhance plant growth, reduce fertilizer needs and phosphate pollution
11. Major scientific discovery in cancer research to be honored

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/6/2017)... Boston, Mass. (PRWEB) , ... October 06, 2017 ... ... spotlight female entrepreneurship within the healthcare and technology sector at their fourth annual ... six panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early ...
Breaking Biology Technology:
Cached News: